

Paul Mehta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10106853/publications.pdf>

Version: 2024-02-01

29
papers

821
citations

623734

14
h-index

552781

26
g-index

30
all docs

30
docs citations

30
times ranked

924
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2023, 24, 108-116.	1.7	22
2	Case-control study in ALS using the National ALS Registry: lead and agricultural chemicals are potential risk factors. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 190-202.	1.7	11
3	Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 220-225.	1.7	22
4	Incidence of amyotrophic lateral sclerosis in the United States, 2014â€“2016. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 378-382.	1.7	20
5	The Latin American Epidemiology Network for ALS (Laenals). <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 372-377.	1.7	5
6	Evaluation of the Completeness of ALS Case Ascertainment in the US National ALS Registry: Application of the Capture-Recapture Method. <i>Neuroepidemiology</i> , 2022, 56, 104-114.	2.3	5
7	Risk factors for amyotrophic lateral sclerosis: A regional United States caseâ€“control study. <i>Muscle and Nerve</i> , 2021, 63, 52-59.	2.2	36
8	The Incidence of Amyotrophic Lateral Sclerosis in Ohio 2016â€“2018: The Ohio Population-Based ALS Registry. <i>Neuroepidemiology</i> , 2021, 55, 196-205.	2.3	5
9	Reproductive History and Age of Onset for Women Diagnosed with Amyotrophic Lateral Sclerosis: Data from the National ALS Registry: 2010â€“2018. <i>Neuroepidemiology</i> , 2021, 55, 416-424.	2.3	4
10	Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registryâ€™s Research Notification Mechanism. <i>Journal of Medical Internet Research</i> , 2021, 23, e28021.	4.3	4
11	Recruitment of population-based controls for ALS cases from the National ALS Registry. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 395-400.	1.7	3
12	History of vigorous leisure-time physical activity and early onset amyotrophic lateral sclerosis (ALS), data from the national ALS registry: 2010â€“2018. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 1-10.	1.7	8
13	Analysis of Biospecimen Demand and Utilization of Samples from the National Amyotrophic Lateral Sclerosis Biorepository. <i>Biopreservation and Biobanking</i> , 2021, 19, 432-437.	1.0	2
14	Increasing Patient Self-Enrollment in the National Amyotrophic Lateral Sclerosis Registry: Lessons Learned From a Direct to Provider Campaign. <i>Journal of Patient Experience</i> , 2020, 7, 71-82.	0.9	0
15	Keratinous biomarker of mercury exposure associated with amyotrophic lateral sclerosis risk in a nationwide U.S. study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 420-427.	1.7	13
16	Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010â€“2015. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 413-420.	1.7	32
17	Amyotrophic lateral sclerosis among patients with a Medicare Advantage prescription drug plan; prevalence, survival and patient characteristics. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 251-259.	1.7	8
18	â€œALS reversalsâ€ demographics, disease characteristics, treatments, and co-morbidities. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 495-499.	1.7	33

#	ARTICLE	IF	CITATIONS
19	Evaluating the completeness of the national ALS registry, United States. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 112-117.	1.7	17
20	Estimation of the Prevalence of Amyotrophic Lateral Sclerosis in the United States Using National Administrative Healthcare Data from 2002 to 2004 and Capture-Recapture Methodology. Neuroepidemiology, 2018, 51, 149-157.	2.3	22
21	Amyotrophic Lateral Sclerosis Mortality in the United States, 2011â€“2014. Neuroepidemiology, 2018, 51, 96-103.	2.3	18
22	A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 126-133.	1.7	29
23	Prevalence of Amyotrophic Lateral Sclerosis â€” United States, 2014. Morbidity and Mortality Weekly Report, 2018, 67, 216-218.	15.1	218
24	Prevalence of Amyotrophic Lateral Sclerosis â€” United States, 2015. Morbidity and Mortality Weekly Report, 2018, 67, 1285-1289.	15.1	107
25	CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions. Morbidity and Mortality Weekly Report, 2017, 66, 1379-1382.	15.1	13
26	Preliminary Results of National Amyotrophic Lateral Sclerosis (ALS) Registry Risk Factor Survey Data. PLoS ONE, 2016, 11, e0153683.	2.5	18
27	Prevalence of Amyotrophic Lateral Sclerosis â€” United States, 2012â€“2013. MMWR Surveillance Summaries, 2016, 65, 1-12.	34.6	80
28	Quantifying a Nonnotifiable Disease in the United States. JAMA - Journal of the American Medical Association, 2014, 312, 1097.	7.4	20
29	Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011. MMWR Supplements, 2014, 63, 1-14.	35.0	46